JP2013536837A5 - - Google Patents

Download PDF

Info

Publication number
JP2013536837A5
JP2013536837A5 JP2013527062A JP2013527062A JP2013536837A5 JP 2013536837 A5 JP2013536837 A5 JP 2013536837A5 JP 2013527062 A JP2013527062 A JP 2013527062A JP 2013527062 A JP2013527062 A JP 2013527062A JP 2013536837 A5 JP2013536837 A5 JP 2013536837A5
Authority
JP
Japan
Prior art keywords
composition
inhibitor
disulfiram
selegiline
aldehyde dehydrogenase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013527062A
Other languages
English (en)
Japanese (ja)
Other versions
JP6355921B2 (ja
JP2013536837A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/001529 external-priority patent/WO2012050594A1/en
Publication of JP2013536837A publication Critical patent/JP2013536837A/ja
Publication of JP2013536837A5 publication Critical patent/JP2013536837A5/ja
Application granted granted Critical
Publication of JP6355921B2 publication Critical patent/JP6355921B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013527062A 2010-09-01 2011-08-31 コカイン嗜癖の治療 Expired - Fee Related JP6355921B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37909510P 2010-09-01 2010-09-01
US61/379,095 2010-09-01
PCT/US2011/001529 WO2012050594A1 (en) 2010-09-01 2011-08-31 Treatment for cocaine addiction

Publications (3)

Publication Number Publication Date
JP2013536837A JP2013536837A (ja) 2013-09-26
JP2013536837A5 true JP2013536837A5 (enExample) 2014-09-25
JP6355921B2 JP6355921B2 (ja) 2018-07-11

Family

ID=45938591

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013527062A Expired - Fee Related JP6355921B2 (ja) 2010-09-01 2011-08-31 コカイン嗜癖の治療

Country Status (9)

Country Link
US (1) US20130165511A1 (enExample)
EP (2) EP3170499A1 (enExample)
JP (1) JP6355921B2 (enExample)
KR (1) KR20130132774A (enExample)
AU (3) AU2011314358B2 (enExample)
CA (1) CA2809966C (enExample)
DK (1) DK2611440T3 (enExample)
PT (1) PT2611440T (enExample)
WO (1) WO2012050594A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2501234T (lt) * 2009-11-20 2017-12-11 Tonix Pharma Holdings Limited Būdai ir kompozicijos, skirti simptomų, susijusių su potrauminiu streso sutrikimu, gydymui naudojant ciklobenzapriną
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
PL3650081T3 (pl) 2013-03-15 2024-06-24 Tonix Pharma Holdings Limited Eutektyczne preparaty chlorowodorku cyklobenzapryny i mannitolu
MY186047A (en) 2014-09-18 2021-06-17 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
CN118267382A (zh) 2017-12-11 2024-07-02 通尼克斯制药控股有限公司 用于痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗
CN113811358A (zh) 2019-03-26 2021-12-17 通尼克斯制药控股有限公司 S-(n,n-二乙基氨基甲酰基)谷胱甘肽的盐形式
US11724486B2 (en) * 2019-07-09 2023-08-15 Kyndryl, Inc. Printing customized medication based on current user data and medical records of the user

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155584A (en) 1962-12-03 1964-11-03 Abbott Lab Compositions and method of inhibiting monoamine oxidase and treating hypertension
SE404186B (sv) 1975-06-09 1978-09-25 Astra Laekemedel Ab Forfarande for framstellning av cyklopropanolderivat
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
WO1992021333A2 (en) 1991-05-24 1992-12-10 Pharmavene, Inc. Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors
US5204369A (en) 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
US6319954B1 (en) 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
BR9501972A (pt) 1995-05-09 1997-08-26 Tostes Luiz Roberto Mallat Composição farmacêutica metodo para tratamento de dependência ou abuso de álcool e método para tratamento de distúrbios psiquiátricos geneticamente relacionados ao alcoolismo
CA2244253C (en) 1996-03-15 2002-11-12 Somerset Pharmaceuticals, Inc. Method for preventing and treating peripheral neuropathy by administering selegiline
US6255497B1 (en) 1997-04-29 2001-07-03 The Endowment For Research In Human Biology, Inc. Method for the inhibition of ALDH-I useful in the treatment of alcohol dependence or alcohol abuse
HUP0100115A2 (hu) 1997-10-28 2001-06-28 Schering Corp. Eljárás kóros vágy csökkentésére emlősökben
US6121010A (en) 1998-05-12 2000-09-19 The Endowment For Research In Human Biology Methods and assays useful in the treatment of alcohol dependence or alcohol abuse
FR2788982B1 (fr) 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
AU2002348135A1 (en) * 2001-10-31 2003-05-12 Recovery Pharmaceuticals, Inc. Methods for the treatment of addiction
WO2003039525A1 (en) * 2001-11-05 2003-05-15 Krele Pharmaceuticals Llc Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
CA2414500A1 (en) * 2002-12-17 2004-06-17 Purepharm Inc. Agonist-aversive combination medicines
US20080078382A1 (en) * 2006-09-20 2008-04-03 Lemahieu Edward Methods and Systems of Delivering Medication Via Inhalation

Similar Documents

Publication Publication Date Title
JP2013536837A5 (enExample)
JP2013505282A5 (enExample)
JP2014515373A5 (enExample)
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
JP2010523587A5 (enExample)
JP2014528474A5 (enExample)
JP2013155188A5 (enExample)
JP2018507243A5 (enExample)
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
JP2006504795A5 (enExample)
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
WO2008011426A3 (en) Methods and medicaments for administration of ibuprofen
NZ714963A (en) Compositions and methods for treating anemia
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
JP2015522630A5 (enExample)
FI3746126T3 (fi) Menetelmiä ja koostumuksia uniapnean tai pelkän kuorsauksen hoitamiseksi
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
JP2013516493A5 (enExample)
JP2013541583A5 (enExample)
ME02474B (me) Terapijski režimi
JP2019218379A5 (enExample)
JP2016505050A5 (enExample)
JP2011500589A5 (enExample)
RU2011111792A (ru) Применение парацетамола и ибупрофена в лечении